ISLAMABAD (News Desk) -The Drug Regulatory Authority of Pakistan (DRAP) has issued an urgent warning regarding a defective batch of allergy medicines, including Sapizine 10 mg and Ortizine 10 mg, which are commonly used to treat allergic rhinitis, hives, and other histamine-related reactions. Patients are advised to stop using the affected products immediately.
Read also: DRAP declares three medicines substandard and dangerous
Healthcare professionals and pharmacies have been instructed to enhance vigilance within their supply chains to prevent the circulation of the compromised batch. Any adverse reactions or quality issues associated with the medicines should be reported to the National Pharmacovigilance Centre (NPC) using the Adverse Event Reporting Form or online via DRAP’s reporting portal. Prompt reporting is vital to protect patient health.
Consumers who have taken the affected medicines are urged to contact their physician or healthcare provider if they experience any issues potentially linked to the products. DRAP also emphasized that all therapeutic products should be purchased only from authorized, licensed pharmacies, and their authenticity and condition should be carefully verified. Patients with doubts about their medicines are encouraged to consult their pharmacist.
Further information on reporting procedures and the affected batch is available through DRAP’s official channels. The authority continues to monitor the situation closely and remains committed to ensuring the safety, efficacy, and quality of medicines available to the public.
